MACULAR THICKNESS BY USING SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY IN CHILDREN AND ADOLESCENTS

imagePurpose:

To determine the distribution of macular and cube thickness and their normal range in the students aged 9 years to 15 years and to investigate their associated demographic and biometric factors.

Methods:

This study was based on the data of the second phase of the Shahroud School Children Eye Cohort Study, conducted in 2018. After measurements of visual acuity, biometry, and subjective and cycloplegic refraction, retinal examination was performed using the Zeiss Cirrus HD 4000 optical coherence tomography.

Results:

The data of 5,043 right eyes were analyzed after applying the exclusion criteria. The central macular thickness was 239 ± 19.35 μm. The mean cube volume and cube thickness were 9.94 ± 0.44 and 278 ± 12.20, respectively. According to multiple linear regression analysis, the central macular thickness was significantly lower in girls (coefficient [β]: −9.18; P

IMPACT OF COVID-19 PANDEMIC LOCKDOWNS ON VISUAL ACUITY OF PATIENTS WITH NEOVASCULAR AMD: A Large Cohort

imagePurpose:

Evaluating the impact of delayed care, secondary to coronavirus disease 2019 (COVID-19) pandemic lockdowns, on visual acuity in previously treated neovascular age-related macular degeneration (nAMD) patients.

Methods:

This was a multicenter, retrospective, study of patients with nAMD previously treated with anti-VEGF injections who were followed up during 2019 (pre–COVID-19) and compared with patients with nAMD during 2020 (COVID-19).

Results:

A total of 1,192 patients with nAMD with a mean age of 81.5 years met the inclusion criteria. Of these, 850 patients were assessed in 2019 (pre–COVID-19) and 630 patients were assessed in 2020 (COVID-19). Three hundred eight patients were assessed through both 2019 and 2020 and thus were included in both cohorts. There was no significant difference between 2020 and 2019 in baseline and change in best-corrected visual acuity (BCVA; P = 0.342 and P = 0.911, respectively). The mean number of anti-VEGF injections was significantly lower (5.55 vs. 6.13, P